Prosecution Insights
Last updated: May 29, 2026

Examiner: SCHLOOP, ALLISON ELIZABETH

Tech Center 1600 • Art Units: 1682 1683

This examiner grants 62% of resolved cases

Performance Statistics

61.8%
Allow Rate
+1.8% vs TC avg
83
Total Applications
+56.5%
Interview Lift
1407
Avg Prosecution Days
Based on 34 resolved cases, 2023–2026

Rejection Statute Breakdown

9.9%
§101 Eligibility
2.9%
§102 Novelty
48.3%
§103 Obviousness
11.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17915167 METHODS OF PROFILING TRANSLATION RATE Non-Final OA The Regents of the University of California
17798506 IMAGING AND SEQUENCING PROTEIN-DNA INTERACTIONS IN SINGLE CELLS USING INTEGRATED MICROFLUIDICS Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18361797 SYSTEM FOR PERFORMING NUCLEIC ACID AMPLIFICATION ASSAYS Non-Final OA GEN-PROBE INCORPORATED
19240318 NEOANTIGEN IMMUNOTHERAPY Final Rejection Gradalis, Inc.
17924640 METHOD FOR DETECTING PARKINSON'S DISEASE Final Rejection JUNTENDO EDUCATIONAL FOUNDATION
17771772 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ESOPHAGEAL CANCER Non-Final OA THE JOHNS HOPKINS UNIVERSITY
17629255 METHOD FOR SPATIALLY BARCODING CELLS IN TISSUE SLICES Final Rejection University of Washington
17535204 APPARATUS AND METHOD FOR GENE AMPLIFICATION Final Rejection AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18332359 A MULTIPLEX CRISPR BASED ASSAY FOR THE SIMULTANEOUS DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE Non-Final OA The Penn State Research Foundation
17923700 METHODS AND COMPOSITIONS FOR HIGH-FIDELITY SEQUENCE ANALYSIS OF INDIVIDUAL LONG AND ULTRALONG NUCLEIC ACID MOLECULES Non-Final OA Northeastern University
18107877 Methods and Systems for Detecting Methylation of Fragile X Non-Final OA Laboratory Corporation of America Holdings
17560724 COMPOSITIONS AND METHODS FOR DETECTION OF BACTERIA AND FUNGI ASSOCIATED WITH BACTERIAL AND CANDIDA VAGINOSIS Non-Final OA Roche Molecular Systems, Inc.
18289869 ENDOCRINE TREATMENT OF HORMONE RECEPTOR POSITIVE BREAST CANCER TYPED AS HAVING A LOW RISK OF RECURRENCE Non-Final OA Agendia N.V.
17629895 COMPOSITIONS FOR DETECTION OF DNA AND METHODS OF USE THEREOF Non-Final OA Mammoth Biosciences, Inc.
17762281 SOLUBLE MEDIATORS FOR PREDICTING SYSTEMIC LUPUS ERYTHEMATOSUS ACTIVITY EVENTS Final Rejection Oklahoma Medical Research Foundation
18111070 METHODS OF ANCHORING FRAGMENTED NUCLEIC ACID TARGETS IN A POLYMER MATRIX FOR IMAGING Final Rejection Vizgen, Inc.
17957643 SEQUENCING OF VIRAL DNA FOR PREDICTING DISEASE RELAPSE Final Rejection GRAIL, Inc.
17458194 Sample Validation for Cancer Classification Final Rejection GRAIL, Inc.
18054676 CELL-FREE DNA SIZE DETECTION Non-Final OA AccuraGen Holdings Limited
17995855 ENDOGENOUS RETROVIRUSES FOR THE DETECTION, DIAGNOSIS, AND PROGNOSIS OF CANCER Non-Final OA SunnyBay BioTech, Inc.
17634124 METHOD FOR DIAGNOSING BREAST CANCER Final Rejection Albert-Ludwigs-Universitaet Freiburg
17680931 Gene Expression Inflammatory Age and Its Uses Non-Final OA Edifice Health, Inc,
17634841 Method and Apparatus for Multi-Omic Simultaneous Detection of Protein Expression, Single Nucleotide Variations, and Copy Number Variations in the Same Single Cells Non-Final OA Mission Bio, Inc.
17337274 PROGRAMMABLE ARRAYS Final Rejection Engineering Arts LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month